Chloë May

66 Case report: successful targeted treatments in NTRK fusion and BRAFV600E mutant gliomas

Abstract Introduction It is rare to find targetable mutations in gliomas. The evidence for using targeted agents remains limited. NICE recommends performing Next Generation and Whole Genome Sequencing (NGS, WGS) for all patients with brain tumours, to identify targets for treatme...

69 Review of outcomes at a tertiary cancer centre of procarbazine (third line) and etoposide (fourth line) chemotherapy for recurrent gliomas

Abstract Introduction There is no standard recommended third- or fourth-line chemotherapy treatment for patients with recurrent gliomas. At our tertiary cancer centre, CCNU, procarbazine and etoposide are commonly used sequentially as second-, third- and fourth-line treatments. T...